Open AccessLinezolid Dampens Neutrophil-Mediated Inflammation in Methicillin-Resistant Staphylococcus aureus-Induced Pneumonia and Protects the Lung of Associated Damages
Author(s) -
Cédric Jacqueline,
Alexis Broquet,
Antoine Roquilly,
Marion Davieau,
J. Caillon,
Frédéric Altare,
G. Potel,
Karim Asehnoune
Publication year - 2014
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiu145
Subject(s) - linezolid , medicine , proinflammatory cytokine , staphylococcus aureus , vancomycin , methicillin resistant staphylococcus aureus , pneumonia , immunology , microbiology and biotechnology , myeloperoxidase , inflammation , biology , bacteria , genetics
Linezolid is considered as a therapeutic alternative to the use of glycopeptides for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). Clinical studies reported a potent survival advantage conferred by the oxazolidinone and called into question the use of glycopeptides as first-line therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom